...
首页> 外文期刊>Europace: European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology >Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation.
【24h】

Propofol sedation administered by cardiologists without assisted ventilation for long cardiac interventions: an assessment of 1000 consecutive patients undergoing atrial fibrillation ablation.

机译:由心脏病专家在无辅助通气的情况下进行的丙泊酚镇静用于长时间的心脏干预:评估连续1000例接受房颤消融的患者。

获取原文
获取原文并翻译 | 示例
           

摘要

Patients can expect a cure from atrial fibrillation (AF) with ablation. Procedural safety and success depend on patient comfort, compliance, and immobility. This is difficult to achieve with benzodiazepine and opiate boluses that are the mainstay of current practice. We sought to determine the safety and efficacy of propofol infusion sedation administered to patients without assisted ventilation for AF ablation.Procedural data from 1000 consecutive patients undergoing AF ablation were analysed. Sedation with 2% propofol was used in all procedures without assisted ventilation and was administered, monitored, and controlled by electrophysiologists. Primary outcome measures were adverse sedative affects including (i) respiratory depression (SpO(2)< 90% for >20 s) and (ii) persistent hypotension [systolic blood pressure (SBP)<90 mmHg at minimum sedation level]. Secondary endpoints included full recovery within 60 min and procedural complications. Of 1000 ablations, 506 ablations were performed for persistent and 494 for paroxysmal AF. Average patient age was 60.1 ± 11.3 years (72.3% male). Propofol was commenced in all patients at a mean infusion rate of 18.5 ± 4.8 mL/h with a mean baseline SBP of 140.3 ± 19.9 mmHg. Mean procedure time was 148.7 ± 57.7 min. Adverse sedative effects necessitating cessation of propofol and switch to midazolam bolus sedation occurred in 15.6% of patients (13.6% due to persistent hypotension, 1.9% due to respiratory depression, and 0.1% due to hypersalivation). Patients who had persistent hypotension were older (62.9 ± 11.2 vs. 60.0 ± 11.4 years, P= 0.011) and more likely to be female (39.5 vs. 23.7%, P< 0.001) than those who tolerated propofol. Patient age correlated to maximum blood pressure drop with propofol (R(2)= 0.101, P< 0.001) and inversely correlated to mean propofol infusion rate (R(2)= 0.066, P< 0.001). No procedures were abandoned due to adverse effects of sedation. All patients recovered within 60 min. Serious procedural complications, unrelated to sedation, occurred in 0.5%, all of whom had pericardial tamponade successfully treated with percutaneous pericardiocentesis.Sedation with 2% propofol infusion administered by cardiologists without assisted ventilation is safe, effective, and practical for use in AF ablation without serious or residual complications. In this setting, persistent hypotension is the most common acute adverse effect requiring cessation of propofol in ~14%.
机译:患者可以通过消融治疗房颤(AF)治愈。程序的安全性和成功取决于患者的舒适度,依从性和行动能力。用苯二氮卓和阿片类药物作为目前的主要手段很难做到这一点。我们试图确定无辅助通气进行房颤消融的患者接受丙泊酚输注镇静的安全性和有效性。分析了连续1000例进行房颤消融的患者的手术数据。在所有过程中,均需在无辅助通气的情况下使用含2%异丙酚的镇静剂,并由电生理学家进行给药,监测和控制。主要的预后指标是镇静剂的不良影响,包括(i)呼吸抑制(SpO(2)<90%,持续时间> 20 s)和(ii)持续性低血压[最低镇静水平时收缩压(SBP)<90 mmHg]。次要终点包括60分钟内完全康复和手术并发症。在1000次消融中,持续性消融506次,阵发性AF消融494次。患者平均年龄为60.1±11.3岁(男性为72.3%)。所有患者均以平均输注速度18.5±4.8 mL / h和平均基线SBP为140.3±19.9 mmHg的情况开始丙泊酚。平均手术时间为148.7±57.7分钟。 15.6%的患者出现了必须停用丙泊酚并改用咪达唑仑大剂量镇静的不良镇静作用(由于持续性低血压导致13.6%,由于呼吸抑制引起的1.9%和因过度流涎引起的0.1%)。与耐受性丙泊酚的患者相比,持续性低血压的患者年龄更大(62.9±11.2 vs. 60.0±11.4岁,P = 0.011),并且女性的可能性更高(39.5 vs. 23.7%,P <0.001)。患者年龄与异丙酚的最大血压下降相关(R(2)= 0.101,P <0.001),与丙泊酚的平均输注速率成反比(R(2)= 0.066,P <0.001)。由于镇静的不良影响,没有放弃任何手术。所有患者均在60分钟内康复。 0.5%发生严重的手术并发症,与镇静无关,所有患者均经心包穿刺心包穿刺成功治疗了心包填塞。由心脏病专家在无辅助通气的情况下使用2%丙泊酚输注进行镇静是安全,有效且实用的,无需进行房颤消融严重或残留的并发症。在这种情况下,持续性低血压是最常见的急性不良反应,需要停止使用异丙酚约14%。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号